Opinion|Videos|January 12, 2024

Dosing JAK Inhibitors in Patients With Myelofibrosis

For most JAK inhibitors dosing starts at the maximum safe dose, while ruxolitinib often requires lower initial doses and dose reductions over the first 12 weeks when cytopenias typically worsen before partially improving, warranting consideration of earlier switching to alternative JAK inhibitors instead of pushing through transfusions.

Related to this article

Image of alcohol
Among U.S. adults with a history of cancer, 45.8% reported drinking alcohol in the past 30 days in both 2016 and 2024, while drinking declined among adults without cancer, according to a study in Cancer Causes & Control of nearly 4 million adults.